Literature DB >> 8788156

High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.

H I Seifart1, W L Gent, D P Parkin, P P van Jaarsveld, P R Donald.   

Abstract

The basic principle of derivatization of a hydrazide moiety with an aldehyde as applied in the method developed by Lacroix et al. [J. Chromatogr., 307 (1984) 137-144] for the quantitation of isoniazid and acetylisoniazid was improved by modification, standardization and extension to allow quantitation of hydrazine in patient samples. It could be shown that 40 microliters of 1% methanolic cinnamaldehyde per 200 microliters of deproteinized analysate gave maximal chromophoric isoniazid-cinnamaldehyde conjugate, read at 340 nm. The hydrolytic loss of isoniazid, crucial to the quantitation of acetylisoniazid, could be compensated for by introduction of an appropriate set of calibration curves. Although the method described here allows quantitation of monoacetylhydrazine and diacetylhydrazine, in addition to hydrazine, in mono-spiked samples, the method cannot be used for the quantitation of the acetylated metabolites of hydrazine in patient samples because of a lack of specificity. Linear calibration curves in the range 1-25 micrograms/ml for isoniazid and acetylisoniazid, 10-400 ng/ml for hydrazine and 50-1000 ng/ml for monoacetylhydrazine and diacetylhydrazine, could be constructed; analyte recoveries approaching 100% could be achieved in all instances.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788156     DOI: 10.1016/0378-4347(96)82886-6

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  11 in total

1.  Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry.

Authors:  M Lisa Manier; Michelle L Reyzer; Anne Goh; Veronique Dartois; Laura E Via; Clifton E Barry; Richard M Caprioli
Journal:  J Am Soc Mass Spectrom       Date:  2011-05-13       Impact factor: 3.109

2.  Electrochemical determination of hydrazine using a ZrO2 nanoparticles-modified carbon paste electrode.

Authors:  Sayed Zia Mohammadi; Hadi Beitollahi; Elina Bani Asadi
Journal:  Environ Monit Assess       Date:  2015-02-19       Impact factor: 2.513

3.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

4.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

5.  The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Authors:  Rui Zhu; Jennifer J Kiser; Heiner I Seifart; Cedric J Werely; Charles D Mitchell; David Z D'Argenio; Courtney V Fletcher
Journal:  J Clin Pharmacol       Date:  2011-05-10       Impact factor: 3.126

6.  Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; T P Kanyok; L H Danziger; A Venter; F J Botha; D P Parkin; H I Seifart; B W Van De Wal; J S Maritz; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Authors:  Jennifer J Kiser; Rui Zhu; David Z DʼArgenio; Mark F Cotton; Raziya Bobat; George D McSherry; Shabir A Madhi; Vincent J Carey; Heiner I Seifart; Cedric J Werely; Courtney V Fletcher
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

8.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Authors:  A Bekker; H S Schaaf; H I Seifart; H R Draper; C J Werely; M F Cotton; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

10.  The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Authors:  P R Donald; D P Parkin; H I Seifart; H S Schaaf; P D van Helden; C J Werely; F A Sirgel; A Venter; J S Maritz
Journal:  Eur J Clin Pharmacol       Date:  2007-05-16       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.